Trial
NCT02389985
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NewLink Genetics Corporation
Collaborators
—
Condition
Ovarian Cancer
Intervention
CRLX101
Why stopped
Company decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-18